DENTSPLY International Inc. (NASDAQ:XRAY) Reviewed By Analysts

Author

30 July, 2017

DENTSPLY SIRONA Inc. (XRAY), a part of Healthcare sector and belongs to Medical Instruments & Supplies industry; ended its day with gain 0.57% and finalized at the price of $63.05. (NASDAQ:XRAY) by 99.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

COPYRIGHT VIOLATION NOTICE: "DENTSPLY SIRONA Inc".

A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in DENTSPLY SIRONA by 2.7% in the first quarter. Atria Investments LLC boosted its position in shares of DENTSPLY SIRONA by 1.5% in the second quarter. Penserra Capital Management LLC increased its position in DENTSPLY SIRONA by 9.5% in the first quarter. Clearbridge Investments LLC now owns 5,258,060 shares of the medical instruments supplier's stock valued at $328,313,000 after buying an additional 1,353,040 shares in the last quarter. TNB Financial acquired a new position in shares of DENTSPLY SIRONA during the first quarter valued at approximately $259,000. Finally, Renaissance Technologies LLC increased its position in DENTSPLY SIRONA by 246.0% in the first quarter. Renaissance Technologies LLC now owns 1,044,558 shares of the medical instruments supplier's stock valued at $65,222,000 after buying an additional 742,700 shares in the last quarter. Institutional owners hold 97.50% stake in the company, while insiders ownership held at 0.70%.

Shares of DENTSPLY SIRONA Inc. The 50 day SMA of the stock is price of $64.03 and a two hundred day SMA of $62.05. The stock is now trading -5.97% away from the 52-week high and separated 65.38% from the 52-week low. The firm has a market capitalization of $14.45 billion, a price-to-earnings ratio of 40.57 and a beta of 1.27.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Tuesday, May 9th.

Last time, the company failed Wall Street by reporting EPS of $0.49, smashing the consensus of $0.50 per share. Currently, DENTSPLY SIRONA Inc.net profit margin for the 12 months is at 9.44%. The company had revenue of $900.50 million for the quarter, compared to the consensus estimate of $916.55 million. The company's stock has a normal trading capacity of 1.25M shares while the relative volume is 0.96. The business's revenue was up 16.6% on a year-over-year basis. On average, analysts expect that DENTSPLY SIRONA will post $2.84 earnings per share for the current year. The dividend will be $0.088 per share for the quarter or $0.35 on an annualized basis. Thestreet.com's news article titled: "Sirona Dental Systems (SIRO) Stock Falls Following Dentsply Merger" with publication date: September 16, 2015 was also an interesting one. The value of the investment in DENTSPLY SIRONA Inc. increased from $22,722,000 to $29,572,000 a change of $6,850,000 for the reporting period.

WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & global trademark and copyright legislation.

DENTSPLY SIRONA Inc. shares had a trading volume of 70K by the end of trading on Friday.

Several equities analysts recently commented on the stock. Moreover, De Burlo Group Inc has 0.7% invested in the company for 49,650 shares. Credit Suisse Group restated an "outperform" rating and set a $75.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a report on Thursday, July 13th. Cleveland Research upgraded DENTSPLY SIRONA from a "neutral" rating to a "buy" rating in a report on Tuesday, May 23rd. The latest reports which are outstanding on Wednesday 26th of July state 6 analysts have a rating of "strong buy", 4 analysts "buy", 5 analysts "neutral", 1 analysts "sell" and 0 analysts "strong sell". Finally, HC Wainwright initiated coverage on DENTSPLY SIRONA in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. On November 1 the stock rating was upgraded from "Equal-weight" to "Overweight" with a current price target of $69.00 in an announcement from Morgan Stanley. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. Additionally, its consumable medical device products are used for urological and surgical applications.


More news


  • Russian deputy PM's refused entry to European Union  airspace

    Russian deputy PM's refused entry to European Union airspace

    Bucharest said Rogozin was on an European Union sanctions list imposed after Moscow's illegal annexation of Crimea in 2014. The plane landed in Minsk, after which the deputy prime minister flew to Moscow from the Belarusian capital by Aeroflot.
    Houthi Rebels Attack Yemeni Port of Mocha With Boat Bomb

    Houthi Rebels Attack Yemeni Port of Mocha With Boat Bomb

    The AFP reported in October that the Houthis launched a long-range strike firing on Mecca. Mokha has been held by pro-government forces since being retaken in February.
    Titans Agree Upon Four-Year, $60.4M Extension With Jurrell Casey

    Titans Agree Upon Four-Year, $60.4M Extension With Jurrell Casey

    He was a third-round pick by the Titans out of USC in 2011. "We are happy to have him as a Titan for many years to come". He is the team's first back-to-back Pro Bowl defensive player since Albert Haynesworth in 2007-08.
  • Arsene Wenger sends fresh message to Arsenal fans about Alexis Sanchez

    Arsene Wenger sends fresh message to Arsenal fans about Alexis Sanchez

    Speaking at his post-match news conference, Wenger said of Sanchez's situation: "There's no development, it's always the same". Sanchez was set to report back for pre-season on Sunday after his summer break, but has stayed away because of illness.
    US Senate slaps new sanctions on Russia; Putin vows retaliation

    US Senate slaps new sanctions on Russia; Putin vows retaliation

    If he opts for a veto, the bill can become law anyway if two-thirds of both the House and Senate vote for an override. Trump has denied any collusion between his associates and Moscow and termed the Russian investigation "a witch hunt".
    Iran defies United States  warning, missile tests to continue

    Iran defies United States warning, missile tests to continue

    A defiant Iran vowed on Saturday to press ahead with its missile program and condemned new sanctions passed by the US Congress. The sanctions come as the Trump administration continues debating its Iran policy and whether to scrap the 2015 nuclear deal.
  • Aspen Insurance Holdings Limited (AHL) Stock Rating Upgraded by Zacks Investment Research

    South Dakota Investment Council boosted its stake in shares of Aspen Insurance Holdings Limited by 7.3% in the first quarter. This company shares are 13.19% off its target price of $54.33 and the current market capitalization stands at $2.86B.
    Trump ousts Reince Priebus as chief of staff

    Trump ousts Reince Priebus as chief of staff

    Priebus had initially tried to block Scaramucci from an earlier post in the White House . Trump also promoted his Deputy Sarah sanders as the new White House Press Secretary.
    Anthony Scaramucci Nixes Appearance At Politicon

    Anthony Scaramucci Nixes Appearance At Politicon

    Donald Trump is proving to be a president pathologically incapable of allowing his team to work for him, writes Paul McGeough. Bender added another layer of intrigue to the story, tweeting that Priebus told him he had privately resigned on Thursday.
  • Skinny Repeal Is Dead

    Skinny Repeal Is Dead

    He also said the Senate should consider a reinsurance program for the individual health market - and noted that Republican Sen. John McCain's decisive "no" vote early Friday marked a major turning point in the GOP's seven-year war to destroy Obamacare.
    Trump calls on Senate Republicans to change filibuster rules

    Trump calls on Senate Republicans to change filibuster rules

    Cole said that "unless the Senate does something ", there is nothing further the House can do on that front. Health insurers have until September to finalize their 2018 health plans in many Obamacare marketplaces.
    President Trump receives Russian Federation  sanctions bill for his signature or veto

    President Trump receives Russian Federation sanctions bill for his signature or veto

    The US ambassador to Russia, John Tefft, was summoned to the foreign ministry on Friday morning to be given the news. If the bill obtains enough bipartisan support among lawmakers, however, Congress would be able to override a veto.